Finding a Solution for Valley Fever
David Larwood, CEO, Valley Fever Solutions Bringing new compounds and diagnostics to help detect and treat Valley Fever. VFS has received good support from government grants, and collaborates closely with the Valley Fever Center for Excellence, vfce.arizona.edu. We are moving towards Phase II trials in humans of Nikkomycin-Z, a compound that shows great promise in treating humans or animals infected with Valley Fever.
AZBio and SynCardia on ABC15
By: Christina Estes ABC15 Tucson-based SynCardia Systems was among the companies showcased at the annual AZ Bio Expo.It’s a chance for bioscience and technology companies to learn more about funding opportunities and hear success stories.According to the Arizona BioIndustry Association, our state is getting more federal funding for research and seeing higher job growth in the bioscience industry compared to the national average.“Tucson and Arizona are the international headquarters for the world’s only total artificial heart,” said Don Isaacs, SynCardia vice president of communications. “They replace the exact same parts of the heart as if you had a heart transplant.”The SynCardia heart is made in Arizona using bio-compatible material also made here. Isaacs says they have 82 employees in Arizona and about 80 people currently using the heart. The device is considered a bridge for people awaiting a transplant or a life saver for those who will not get transplants due to age or medical conditions.“There’s only 2,200 hearts available per year in the United States and the level of donors has been the same for the last twenty years,” Isaacs said.SynCardia is also undergoing FDA clinical trials for the world’s first wearable power supply for their temporary artificial heart. ©2007 The E.W. Scripps Co. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. (Republished with permission from ABC15) Read more: http://www.abc15.com/dpp/news/region_southeast_valley/tempe/Arizona-company-SynCardia-Systems-makes-worlds-first-total-temporary-artificial-heart#ixzz2X99ewU3x
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart. The company was formed in 2001 by world-renowned heart surgeon Jack G. Copeland, MD, interventional cardiologist Marvin J. Slepian, MD, and biomedical engineer Richard G. Smith, MSEE, CCE, to commercialize the SynCardia temporary Total Artificial Heart .
A Global Perspective from executives of Arizona’s Bioscience Companies on why they are in Arizona Panelists Bob Bosserman, CEO, Medelis Janet Spear, Plant Manager, Celgene Joan Koerber-Walker, president & CEO, AZBio (moderator) Dr. Ken Wertman, Scientific Director, Sanofi, Oro Valley Dr. Phil Miller, Ventana Filmed live at the 2011 AZBio Expo
AHSC: Helping People Live Better Longer
The Arizona Health Sciences Center at the University of Arizona The Arizona Health Sciences Center (AHSC) at the University of Arizona is a network of health-related organizations and activities unique in the state and region. Arizona’s only academic health sciences center, AHSC is based on the campus of the University of Arizona in Tucson and maintains a growing presence on the Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, AHSC reaches across the state of Arizona and well beyond its borders to provide health-care education, research, patient care and service for Arizonans and their neighbors today and for the future.
Company Presentation: NuvOx
NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.
Linda Hunt of Dignity Health Arizona, 2013 Arizona Bioscience Leader of the Year
The Jon W. McGarity Arizona Bioscience Leader of the Year Award honors the person in Arizona who provided the most outstanding leadership that contributed significantly to development of the State’s bioindustry and/or recognition of the advancement of bioscience in Arizona. Recognizing that collaboration builds a stronger community, Linda Hunt has taken a leadership role to advance healthcare and the biosciences for the people of Arizona. Hunt has worked diligently with legislators, business leaders, educators, scientists and community organizations in order to identify, formulate, and support policies that will give Arizonans better healthcare and raise the bar of knowledge.Hunt has served as the head of Dignity Health in Arizona since 2012. Dignity Health includes three major hospitals in the Valley, St. Joseph’s Hospital and Medical Center and Chandler Regional and Mercy Gilbert Medical Centers. A fourth hospital, St. Joseph’s Westgate, is under construction.